Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Goldstein

Allergy & Immunology Philadelphia, PA Medical Doctor

NPI 1093863334 CMS profile 4667

205 N Broad St, Suite 300, Philadelphia, PA 19107

Open in the dashboard

General payments

$21,566

1,131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Goldstein of Philadelphia, PA is reported in the CMS Open Payments database as having received $21,566 across 1,131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,626 198
2024 General $3,878 225
2023 General $2,808 181
2022 General $2,981 191
2021 General $1,748 110
2020 General $2,395 60
2019 General $4,130 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Goldstein
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Marc Goldstein were reported at $3,626. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Marc Goldstein Allergy & Immunology median Middle half National median
2019 $4,130 $594 $163–$1,512 $163
2020 $2,395 $426 $106–$1,233 $114
2021 $1,748 $638 $157–$1,708 $132
2022 $2,981 $790 $205–$1,961 $149
2023 $2,808 $852 $220–$2,147 $160
2024 $3,878 $865 $203–$2,267 $164
2025 $3,626 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $4,442 325 payments
  2. AstraZeneca Pharmaceuticals LP $3,235 107 payments
  3. CSL Behring $1,813 108 payments
  4. Regeneron Healthcare Solutions, Inc. $1,542 87 payments
  5. FFF Enterprises, Inc. $1,500 3 payments
  6. OptiNose US, Inc. $1,223 76 payments
  7. Genzyme Corporation $950 42 payments
  8. Genentech USA, Inc. $820 47 payments
  9. Pfizer Inc. $721 55 payments
  10. kaleo, Inc. $712 42 payments
  11. Other $4,607 239 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,014 1,104 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 3 payments
  3. Consulting Fee $1,182 3 payments
  4. Education $870 21 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $2,421 193 payments
  2. SYMBICORT $1,518 20 payments
  3. NUCALA $1,367 99 payments
  4. Xhance $1,223 76 payments
  5. DUPIXENT Inflammation And Immunology $1,182 68 payments
  6. DUPIXENT Immunology $1,169 57 payments
  7. Hizentra $997 61 payments
  8. Xolair $870 48 payments
  9. FASENRA $708 34 payments
  10. Haegarda $648 40 payments
  11. Other $10,358 631 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,580

Median for Allergy/ Immunology: 449

Drug cost

$1,179,320

Median for Allergy/ Immunology: $169,700

Branded share of claims

63.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 40 $283,713
Dupixent Syringe Dupilumab Brand 34 $190,755
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 183 $190,533
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 13 $165,495
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 14 $109,814
Breo Ellipta Fluticasone/Vilanterol Brand 144 $83,795
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 49 $30,368
Spiriva Respimat Tiotropium Bromide Brand 28 $20,465
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 70 $14,567
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $12,835

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$840,502

Of which drugs: $545,093

Medicare patients

389

Average age 73

Services billed

37,017

264 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 55%
Ischemic heart disease 32%
COPD 28%
Diabetes 26%
Depression 24%
Osteoporosis 24%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 21 9,934 $296,949
Vaccine for influenza for injection into muscle 90662 Office 38 38 $3,109

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$783 34 —
TRELEGY ELLIPTA
$329 183 —
NUCALA
$298 — —
XOLAIR
$284 — 9,934
Orladeyo
$228 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record